Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Tavapadon, a once-daily oral drug targeting D1/D5 dopamine receptors, is awaiting FDA approval and could be the first new dopamine agonist for Parkinson's disease in decades. Phase 3 TEMPO trials showed meaningful motor improvements both as early-stage monotherapy and as an add-on to levodopa. Experts are cautiously optimistic, though high discontinuation rates and limited long-term data temper enthusiasm.
Parkinson's disease treatment may be on the verge of its first new dopamine agonist strategy in decades. Tavapadon, an investigational once-daily oral drug developed by AbbVie, selectively targets D1/D5 dopamine receptors — a novel mechanism distinct from existing D2/D3 agonists like pramipexole. The FDA is expected to rule on the New Drug Application later this year, following AbbVie's submission in September 2025.
Across three pivotal phase 3 TEMPO trials, tavapadon demonstrated significant motor improvements in early-stage Parkinson's as monotherapy and as an add-on to levodopa in patients experiencing "wearing-off" episodes. Notably, rates of somnolence and impulse control disorders — hallmark side effects of older dopamine agonists — were low. However, discontinuation rates were high (17–24% with tavapadon vs. 4–9% with placebo), mostly during dose titration, and experts caution that 26-week trials may be too short to fully assess neuropsychiatric risks.
By the Numbers:
Why it matters: If approved, tavapadon would be the first PD therapy since rasagiline (2006) cleared for both early monotherapy and adjunctive use — potentially offering neurologists a versatile new tool, especially for younger patients who need once-daily dosing and want to avoid the side effects of older dopamine agonists.
